Saturday 17 October 2026 Export BLCO’s income statement to Excel — free account

Bausch + Lomb Corporation

BLCO Healthcare Medical Instruments & Supplies

Bausch + Lomb Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 6.47% from fiscal 2024. In the quarter to June 2026, revenue grew 9.08%, EPS grew 77.8%, free cash flow grew 251.9% and total debt rose 3.15%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

16.40 0.26 −1.56%

Follow BLCO

Alert me

Market cap: $6.0B
P/E: 0.0×
Fwd P/E: −249×
Dividend yield: —
F-score: 3/9
Altman Z: 0.87
Beneish M: −2.52
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 1.22

Total sells 1.19

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	4	5	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	2	—	—

Insider Ownership 88.78%

Capital & Financial Ratios $m

Market Cap 5,950.00

Revenue 5,324.00

Net Income (163.00)

Free Cash Flow 137.00

Net Debt 4,737.00

Current Ratio 1.55

Debt/Equity 0.79

P/E ratio 0.00

Fwd P/E (249.00)

P/S ratio 1.10

P/B ratio 0.91

Past 5Y EPS Growth —

This Y EPS Growth 55.84%

Next Y EPS Growth 38.96%

Next Y revenue growth 7.68%

Next 5Y EPS Growth 41.94%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 18.73%

10-year low 10-year high

P/B against its own 10 years 72.58%

10-year low 10-year high

EV/Sales against its own 10 years 20.88%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	334	316	397	378
Receivables	839	1,026	1,221	1,160
Inventory	1,028	1,036	976	999
Other	—	—	—	—
	2,742	2,788	2,977	2,922

	2023	2024	2025	Q'26
Payables	522	389	388	426
ST’ Debt	30	40	39	43
Other	—	—	—	—
	1,579	1,738	1,920	1,890

Compound Annual Growth %

	10y	5y	3y
Sales	—	8.38%	10.62%
Cash Flow	—	(11.52%)	(6.39%)
Earnings	—	0.00%	0.00%
Book Value	—	(8.18%)	(2.81%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1,244	1,394	—	—	—
’25	1,137	1,278	1,281	1,405	5,101
’24	1,099	1,216	1,196	1,280	4,791
’23	931	1,035	1,007	1,173	4,146
’22	889	941	942	996	3,768
’21	881	934	949	1,001	3,765

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	32	153	—	—	—
’25	(25)	35	137	136	283
’24	41	15	154	22	232
’23	(56)	(24)	48	15	(17)
’22	3	156	27	159	345
’21	188	250	273	162	873

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(68)	82	—	—	—
’25	(135)	(54)	63	60	(66)
’24	(26)	(57)	94	(70)	(59)
’23	(93)	(54)	15	(69)	(198)
’22	(39)	122	(27)	109	170
’21	143	206	232	83	664

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.20)	(0.04)	—	—	—
’25	(0.60)	(0.18)	(0.08)	(0.16)	(1.02)
’24	(0.48)	(0.43)	0.01	(0.01)	(0.90)
’23	(0.26)	(0.09)	(0.24)	(0.15)	(0.74)
’22	0.06	0.01	(0.05)	0.00	0.02
’21	0.09	0.13	0.18	0.15	0.55

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	—	12.20	14.64	13.16	10.45	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	—	20.20	21.95	21.69	18.55
People
People	Employees	—	—	—	—	—	12,500	12,900	13,300	13,500	13,000
	Revenue/emp, $m	—	—	—	—	0.00	0.30	0.29	0.31	0.35	0.39
Income, $m
Income, $m	Revenue	—	—	—	—	3,412	3,765	3,768	4,146	4,791	5,101
	Gross margin, %	—	—	—	—	62.34	61.04	59.69	60.40	60.93	59.81
	EBT	—	—	—	—	290	318	73	(166)	(234)	(317)
	EBT margin, %	—	—	—	—	8.50	8.45	1.94	(4.00)	(4.88)	(6.21)
	Net income	—	—	—	—	(17)	193	15	(248)	(305)	(352)
	Depreciation	—	—	—	—	442	415	387	412	456	439
Per share, $
Per share, $	Revenue	—	—	—	—	9.75	10.76	10.77	11.83	13.62	14.42
	Earnings	—	—	—	—	(0.05)	0.55	0.02	(0.74)	(0.90)	(1.02)
	Cash flow	—	—	—	—	1.49	2.49	0.99	(0.05)	0.66	0.80
	Capex	—	—	—	—	(0.74)	(0.60)	(0.50)	(0.52)	(0.83)	(0.99)
	Free cash flow	—	—	—	—	0.75	1.90	0.49	(0.56)	(0.17)	(0.19)
	Book value	—	—	—	—	28.54	26.86	20.29	19.74	18.60	18.43
	Shares, m	—	—	—	—	350	350	350	351	352	354
Valuation, ×
Valuation, ×	P/E	—	—	—	—	38.04	38.04	786.00	0.00	0.00	0.00
	P/S	—	—	—	—	1.86	1.86	1.46	1.43	1.33	1.18
	P/B	—	—	—	—	0.97	0.97	0.77	0.86	0.97	0.93
	EV/Sales	—	—	—	—	2.39	2.39	2.01	2.45	2.26	2.10
	EV/FCF	—	—	—	—	18.13	18.13	50.72	(45.55)	(128.83)	(117.89)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	—	522	873	345	(17)	232	283
	Capex	—	—	—	—	(259)	(209)	(175)	(181)	(291)	(349)
	Free cash flow	—	—	—	—	263	664	170	(198)	(59)	(66)
Balance, $m
Balance, $m	Working capital	—	—	—	—	745	536	841	1,163	1,050	1,057
	Total debt	—	—	—	—	—	—	2,436	4,562	4,784	5,082
	Net debt	—	—	—	—	(238)	(177)	2,056	4,228	4,468	4,685
	Shareholders’ equity	—	—	—	—	9,988	9,402	7,101	6,920	6,544	6,519
Returns, %
Returns, %	ROA	—	—	—	—	0.00	1.65	0.05	(2.12)	(2.36)	(2.62)
	ROIC	—	—	—	—	1.67	2.23	1.41	0.73	0.92	0.63
	ROE	—	—	—	—	0.00	1.88	0.07	(3.71)	(4.71)	(5.51)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ALGN Align Technology, Inc.	$10.6B	25.6×	20.7×	+4.32% (above 0%: growing)	−12.21% (below 0%: shrinking)	+85.77% (above 0%: growing)	71.71%	14.58%	Compare
ATR AptarGroup, Inc.	$7.9B	22.2×	21.0×	+6.26% (above 0%: growing)	−18.34% (below 0%: shrinking)	−23.07% (below 0%: shrinking)	35.61%	12.34%	Compare
BLCO Bausch + Lomb Corporation	$6.0B	— (loss-making)	— (loss-making)	+9.08% (above 0%: growing)	n/m	+251.85% (above 0%: growing)	62.20%	5.95%
TFX Teleflex Incorporated	$5.4B	— (loss-making)	45.3×	+28.88% (above 0%: growing)	−17.33% (below 0%: shrinking)	+220.14% (above 0%: growing)	58.16%	12.77%	Compare
MMSI Merit Medical Systems, Inc.	$5.4B	36.4×	23.4×	+9.51% (above 0%: growing)	+18.18% (above 0%: growing)	−25.66% (below 0%: shrinking)	51.37%	14.42%	Compare
STVN Stevanato Group S.p.A.	$5.3B	33.8×	27.5×	+10.46% (above 0%: growing)	−25.00% (below 0%: shrinking)	−167.02% (below 0%: shrinking)	28.75%	12.93%	Compare
ICUI ICU Medical, Inc.	$4.2B	136×	49.5×	+0.51% (above 0%: growing)	−46.85% (below 0%: shrinking)	+655.98% (above 0%: growing)	42.61%	7.09%	Compare
NVST Envista Holdings Corporation	$3.8B	38.8×	24.4×	+7.10% (above 0%: growing)	+106.25% (above 0%: growing)	+37.57% (above 0%: growing)	55.72%	10.99%	Compare
PLSE Pulse Biosciences, Inc	$3.3B	— (loss-making)	— (loss-making)	+4,922.22% (above 0%: growing)	n/m	−45.39% (below 0%: shrinking)	37.10%	(5,823.04%)	Compare
Median of peers	$5.3B	35.1×	24.4×	+8.31%	−17.33%	+7.25%	46.99%	12.56%

All 55 Medical Instruments & Supplies stocks →

Bausch + Lomb Corporation (BLCO) key facts

Strength: Bausch + Lomb Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 6.47% from fiscal 2024.
Bausch + Lomb Corporation (BLCO) is a Medical Instruments & Supplies company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, BLCO traded at $16.40, a market capitalization of $6.0 billion.
Return on equity was −5.51% and debt-to-equity 0.79.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 0.87 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.